distribution (19-65 years) of the cohort were considered representative of the population of blood donors at that time. Blood samples were collected in vacuum tubes (Vacutainer, SST, Becton Dickinson, Meylan, France) and centrifuged, and 1-mL plasma aliquots were stored at −80°C until use. Nucleic acids were extracted as described previously (7) and tested for PARV4 genomic DNA immediately after extraction to avoid freezing/thawing cycles.
Five microliters of the eluted material served for PARV4 DNA detection using real-time PCR TaqMan methods (StepOne Plus, Applied Biosystems, Courtaboeuf, France) and primers (ORF2) compatible with the detection of the 3 virus genogroups described at this time (2, 4, 7) . Two probes were tested in separate amplifi cation assays: PARV4-O (5′-FAM-TGTTCAACTTTCTCAGGTCCT ACCGCCC-TAMRA-3′) (4,7) and PARV4-N (5′-FAM-TCCTACYGCC CSCTCCTCCTTCTT-TAMRA-3′). The second primer was designed after identifi cation and sequencing of several in-house real-time PCR products (GenBank accession nos. FJ883557-61), and more particularly those detectable on agarose gels but showing negative signal with PARV4-O TaqMan assay because of mismatches identifi ed on the probe recognition site (Figure) . Amplifi cation reactions were performed as described previously (7) . Both TaqMan assays were estimated to detect as few as 10 copies of PARV4 DNA per reaction using dilutions of a synthetic template (7) .
Fifteen (4.9%) blood donors gave positive signal with probe PARV4-O; 62 (20.4%) were positive with probe PARV4-N; 6 (2.0%) samples were positive in both assays. Overall prevalence for PARV4 DNA was 24.0% in the blood donors tested.
PARV4 origin of randomly selected PCR products from PARV4-O and PARV4-N TaqMan assays (5 each) was confi rmed after cloning and M13 sequencing. Point mutations located on the PARV4-O recognition site were retrieved in amplicons originating from samples positive with PARV4-N assay ( Figure) . However, subsequent molecular studies aiming to characterize virus strains were not feasible because of the low titer of PARV4 DNA (<500 copies/mL of plasma) in positive samples. No specifi c correlation was identifi ed between sex or geographic origin and PARV4 viremia, whereas analysis of the distribution of PARV4-positive samples in age groups highlighted a relative homogeneity throughout the corresponding cohort.
Our study shows that PARV4 infection is readily detectable in French blood donors. Prevalence results using probe PARV4-O were comparable to those obtained in previous studies involving healthy persons originating from various countries (4-6). Conversely, the high prevalence obtained by using probe PARV4-N was unexpected because only 1 study demonstrated a higher value (45.7%) after the investigation of PARV4 DNA in bone marrow aspirates of AIDS patients from Italy (9) .
This fi nding suggests a larger dispersion of PARV4 than expected initially in the general population and highlights the need for improvement in detection systems directed toward PARV4 DNA, particularly by interlaboratory collaborations, in direct connection with studies investigating PARV4 genetic diversity. These considerations are consistent with the recent description of a new PARV4 genogroup in humans and characterization of highly divergent variants in bovine and porcine species (10) . In addition, such data raise the question of the consequent persistence of PARV4 infection in healthy persons. Future studies need to explore both dispersion and potential clinical impact of PARV4 on infected hosts. We identifi ed 10 patients from the national reference laboratory database with otologic samples yielding M. chelonae-M. abscessus group bacteria during January 1995-June 2007. We resubjected these isolates to molecular identifi cation by rpoB gene sequencing (4) and performed a medical fi le review.
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